NCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
Clinical Trials
11 trialsNCT04439266 2025-11-19
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06357975 2025-10-31
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439253 2025-09-18
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05160922 2025-09-03
Crizotinib Continuation Clinical Study
Pfizer
Phase 4 Active not recruiting
NCT01121588 2025-01-23
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Pfizer
Phase 1 Terminated
NCT01606878 2024-01-05
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02419287 2023-03-06
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
University of Milano Bicocca
Phase 2 Completed
NCT00939770 2020-06-09
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1/2 Completed
NCT02487316 2016-12-30
A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Peking University
Phase 4 Withdrawn